To include your compound in the COVID-19 Resource Center, submit it here.

CLPA reports Phase II/III Aptosyn data

Cell Pathways (CLPA) said that 200 mg of Aptosyn exisulind twice daily significantly reduced median

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE